Expert Interview
Discussing lorundrostat and the Advance-HTN trial for the treatment of hypertension
Ticker(s): MLYSInstitution: Providence St. Joseph Heart Institute
- Medical director of the Center for Cardiovascular Analytics, Research, and Data Science (CARDS) at the Providence St. Joseph Heart Institute in Portland, Oregon and an adjunct faculty member of the Ciccarone Center for the Prevention of Heart Disease at the Johns Hopkins Hospital in Baltimore, Maryland.
- Manages 675 patients with ASCVD & 11 patients with pericarditis.
- Principal clinical interests include identifying, coordinating, and implementing cardiovascular care improvement strategies.
What are your thoughts on aldosterone synthase inhibitors as a treatment option for uncontrolled hypertension, and how do they compare to current options such as spironolactone?
Added By: slingshot_insightsHow do the half-lives of lorundrostat and baxdrostat impact their efficacy, and what are your thoughts on their potential differentiation in trials like ADVANCE-HTN?
Added By: slingshot_insightsHow do you manage potassium levels in clinical practice, particularly when using aldosterone inhibitors, and what are the potential challenges with hyperkalemia?
Added By: slingshot_insightsCan you help us understand the prevalence and target patient population for aldosterone synthase inhibitors, and how do these drugs perform in comparison to spironolactone in terms of efficacy and safety?
Added By: slingshot_insightsWhat is your level of excitement for lorundrostat on a scale from 1 to 10, and what factors could influence the adoption of this new treatment by payers and in clinical practice?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
